https://orcid.org/0000-0002-2006-6467
References
- Ponti G, Manfredini M, Pastorino L, et al. PTCH1 germline mutations and the basaloid follicular hamartoma values in the tumor spectrum of basal cell carcinoma syndrome (NBCCS). Anticancer Res. 2018;38(1):471–476.
- Jansen MHE, Mosterd K, Arits A, et al. Five-year results of a randomized controlled trial comparing effectiveness of photodynamic therapy, topical imiquimod, and topical 5-fluorouracil in patients with superficial basal cell carcinoma. J Invest Dermatol. 2018;138(3):527–533.
- Sinx KAE, Nelemans PJ, Kelleners-Smeets NWJ, et al. Surgery versus combined treatment with curettage and imiquimod for nodular basal cell carcinoma: one-year results of a non-inferiority, randomized controlled trial. J Am Acad Dermatol. 2020;83(2):469–476.
- Samela PC, Tosi V, Cervini AB, et al. Nevoid basal cell carcinoma syndrome: our experience in a pediatric hospital. Actas Dermosifiliogr. 2013;104(5):426–433.
- Accesdata.fda.org [Internet]. Silver Spring (MD): U.S. Food and Drug Administration. [Last updated 2010 Oct, cited 2020 Aug 31]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020723s022lbl.pdf.